Cancer Research Targets Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reisman, D. N.
Right arrow Articles by Weissman, B. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reisman, D. N.
Right arrow Articles by Weissman, B. E.
[Cancer Research 63, 560-566, February 1, 2003]
© 2003 American Association for Cancer Research

Advances in Brief

Loss of BRG1/BRM in Human Lung Cancer Cell Lines and Primary Lung Cancers: Correlation with Poor Prognosis1

David N. Reisman2, Janiece Sciarrotta, Weidong Wang, William K. Funkhouser and Bernard E. Weissman3

Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina 27599-7525 [J. S., W. K. F., B. E. W.]; Laboratory of Genetics, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224 [W. W.]; and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599-7295 [D. N. R., B. E. W.]


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
A role for the SWI/SNF complex in tumorigenesis based on its requirement for retinoblastoma induced growth arrest and p53-mediated transcription and the appearance of tumors in SWI/SNF-deficient mice. In addition, Western blot data have shown that the SWI/SNF ATPase subunits cell, BRG1 and BRM (BRG1/BRM), are lost in ~30% of human non-small lung cancer cell lines. To determine whether loss of expression of these proteins occurs in primary tumors, we examined their expression in 41 primary lung adenocarcinomas and 19 primary lung squamous carcinomas by immunohistochemistry. These analyses showed that 10% of tumors show a concomitant loss of BRG1 and BRM expression. Moreover, patients with BRG1/BRM-negative carcinomas, independent of stage, have a statistically significant decrease in survival compared with patients with BRG1/BRM. This report provides supportive evidence that BRG1 and BRM act as tumor suppressor proteins and implicates a role for their loss in the development of non-small cell lung cancers.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 REFERENCES
 
SWI/SNF is a multimeric chromatin remodeling complex important for gene regulation. Like other proteins involved in gene regulation, the SWI/SNF complex is a potential target for disruption during neoplastic progression. Investigations into the chromosomal aberrations in 22q11.2 region led to the discovery of the SWI/SNF component, SNF5/INI1/BAF47, as a tumor suppressor gene in rhabdoid tumors, rhabdomyosarcomas, and choroid plexus carcinomas (1, 2, 3) . The finding that SNF5/INI1/BAF47 heterozygous mice develop tumors that closely resemble human rhabdoid tumors further supports this notion (4 , 5) . In yeast, the functions of the complex require the functional integrity of the subunits, and loss of any one component is sufficient to alter the function of the complex (6) . Thus, disruption of the SWI/SNF complex by the loss of other subunits may also be associated with human tumorigenesis. To this end, investigations have shown an evolving role for the mutually exclusive SWI/SNF ATPases, BRM (Brahma) and BRG1 (BRM-related gene 1), in growth control and tumorigenesis. Transgenic heterozygous BRG1 mice (BRG1+/-) form s.c. tumors resembling breast cancer (7) . Although BRM null transgenic mice (BRM-/-) do not form tumors, the loss of expression of BRM causes cells to have an altered proliferation and impaired cell cycle control (8) . Moreover, the BRG1 and BRM interact with key regulatory proteins, including RB4 protein, p53, p107, p130 (RB2), BRCA1, and ß-catenin (2 , 9) . Specifically, BRG1 protein is required for RB-induced growth inhibition, p53-mediated transcription and BCRA1-controlled gene expression (10, 11, 12) . Thus, the loss of BRG1 and BRM expression should impact on a multitude of growth regulatory pathways. These data provide a rationale for BRG1 and BRM to function as tumor suppressor proteins.

Although these and other data appear compelling, establishing BRG1 and BRM as bona fide tumor suppressors also requires demonstrating their loss of expression in primary tumors. Therefore, based on data showing loss of BRG1 and BRM expression in ~30% of human NSCLC cell lines and published data showing loss of heterozygosity surrounding the BRG1 and BRM loci in human lung cancers (13) we conducted immunohistochemical staining for BRG1 and BRM on 60 NSCLC samples taken from patients that underwent curative resections for stage I–IIIA tumors. We observed loss of BRG1/BRM expression in 6 of 60 tumor samples (~10%), suggesting that BRG1/BRM loss in tumor cell lines does not arise as a tissue-culture artifact. Consistent with cell line data, loss of BRG1 expression occurred concomitantly with loss of BRM expression. Clinically, loss of BRG1/BRM expression in NSCLC was associated with a significantly worse patient survival compared with the survival of patients with BRG1/BRM-positive tumors. These data additionally support that BRG1/BRM act as tumor suppressor proteins and that loss of function of these proteins may potentially impact the clinical outcome of NSCLC.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 REFERENCES
 
Immunohistochemical Staining.
Normal human tissue and paired NSCLCs were collected from University of North Carolina archives, and 5-µm sections were cut and mounted on Probe On Plus slides (Fisher Scientific). After deparaffinization in xylene, slides were rehydrated and placed in running water. Slides were placed in a MicroProbe slide holder (Fisher Scientific), and the appropriate antigen retrieval buffer was applied, BRG1 in AR-10 (BioGenex) and BRM in Citra (BioGenex). All slides were then placed in a Black and Decker steamer for 30 min and allowed to cool for 20 min. After multiple rinsing in Automation Buffer (Biomeda), endogenous peroxidase was quenched using a 3% solution of hydrogen peroxide. Excess protein was then blocked using normal goat serum (BioGenex), and the sections were then exposed to the primary antibodies, BRG1 1:1000 (a gift from Pierre Chambon) or BRM 1:50 (Transduction Laboratories) for 30 min at 37°C. After rinsing in Automation buffer, slides were then placed in the secondary antibody (BioGenex Super Sensitive Multi Link) for 7 min at 37°C, rinsed in Automation Buffer, and then incubated in the label (BioGenex Super Sensitive HRP) for 7 min at 37°C. After again rinsing in Automation Buffer, detection of the antibody/antigen complex was visualized using 3,3' diaminobenzidine. Slides were then lightly counterstained in Mayer’s hematoxylin, rinsed, dehydrated, cleared, and mounted.

Tumor Samples.
Tumor samples banked at the University of North Carolina from 1997–1999 were randomly selected. The specimens were derived from patients with stage I–IIIA NSCLC. Internal Review Board approval was obtained before our analysis.

Statistical Analyses.
The Kaplan-Meier (or product limit) method was used to estimate the survivorship function. We used the log-rank test to identify possible differences between estimated survival curves. All analyses were performed with SAS statistical software, version 8.2, from SAS Institute (Cary, NC).


   Results
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 REFERENCES
 
To determine whether SWI/SNF complex members other than INI1/SNF5/BAF47, a known tumor suppressor gene, were lost in human carcinomas, we screened a variety of human cell lines derived from different primary carcinomas (14) . We found that loss of expression of BRM and BRG1 appears more frequently than the loss of other complex subunits, occurring in 10% (8 of 80) of human tumor cell lines (14) . In these cell lines, the down-regulation of BRG1 occurred concomitantly with down-regulation of BRM (15) . Also, four of eight BRG1/BRM-deficient cell lines were derived from lung adenocarcinomas, representing 33% (4 of 12) of NSCLCs overall. Similarly, Wong et al. (16) showed BRG1 has been mutated in 14% (2 of 14) of NSCLC cell lines and 10% (18 of 180) of human tumor cell lines using high throughput DNA sequencing. Subsequent Western blotting analysis of these cell lines showed that only the lung cancer cell lines (A427 and H1299) harboring BRG1 mutations had low to no expression of both BRG1 and BRM (17) . Taken together, these cumulative data show that loss of BRG1 and BRM expression occurs in ~30% (6 of 20) of human lung cancer cell lines (Table 1)Citation .


View this table:
[in this window]
[in a new window]

  		Table 1 Expression of BRG1 and BRM in human lung cancer cell lines

A total of 20 human NSCLC lines have been screened by sequencing for BRG1 mutations and/or western blotting for BRM and BRG1 protein expression. Six human NSCLCa cell lines (rows 1–4, 17, 19) (~30%) have concomitant significantly reduced to no expression of BRG1 and BRM by Western blotting. Wong et al. (15) found mutations in the BRG1 gene in two of these cell lines (A427 and H1299). ND, not determined.

 
Primary Human NSCLC Show Reduced or Absent BRG1 and BRM Expression.
To establish that loss of BRG1/BRM occurs in primary tumors and does not arise from the establishment of the cell lines, we examined the expression of BRM and BRG1 in 41 primary lung adenocarcinoma cancers and 19 primary lung squamous cell carcinomas by immunohistochemistry. By using a BRG1-specific antibody, we first detected BRG1-negative tumors. Staining the same BRG1-negative tumors with a second antibody that recognizes a conserved shared BRG1/BRM epitope, allowed us to unambiguously determine the presence or absence of BRM expression. In addition, when staining was not detected with this second antibody, it also confirmed that these tumors were negative for BRG1.

Using the BRG1 specific antibody, we detected loss of BRG1 expression in 6 of 60 tumors (~10%; Figs. 1,A–FCitation , and 2Citation ). These 6 tumors also showed no positive signal with the second antibody showing that neither BRG1 nor BRM expression was present (Figs. 1, G–LCitation , and 2Citation ). Moreover, these tumors did not show a continuum of staining with either of these antibodies such that the positively stained tumors are distinctly grouped from the negatively stained tumors (Fig. 2)Citation .




View larger version (331K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. BRG1 and BRM expression in primary NSCLCs. Forty-one adenocarcinomas and 21 squamous cell carcinomas were stained for BRG1 expression using a BRG1-specific monoclonal antibody. Six tumors were devoid of BRG1 expression, whereas the normal bronchial epithelium and/or infiltrating lymphocytes within these samples showed specific nuclear staining (as illustrated in the 3 tumors B, D, and F). In comparison, 54 of the tumors showed preferential nuclear staining as illustrated in A, C, and E. The same 6 tumors, which were devoid of BRG1 expression, were stained with a BRM/BRG1 antibody that detects both proteins. These tumors were also found to have minimal to no BRM expression as illustrated in the 3 tumors H, J, and L. Internal positive controls can be seen in these samples [bronchus (J) and lymphocytes (H and L)]. The other 54 tumors show specific nuclear staining as exemplified in tumors shown in G, I, and K.

 


View larger version (50K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Comparison of BRG1 and BRM expression in lung adenocarcinomas and lung squamous cell carcinomas. A shows quantitative expression (staining intensity) of BRG1 and BRM in lung adenocarcinomas and lung squamous cell carcinomas. Two independent pathologists evaluated the slides. A value for each sample was derived by estimating the percentage of cells (in decade increments, 0–100%) showing nuclear immunoreactivity and then multiplying by their average intensity (range, 0–3; A). This product is referred to as Intensity. B and C show the distribution of BRG1 and BRM/BRG1 staining when intensity is graphed versus percentage of staining. Adenocarcinomas and squamous cell carcinomas are denoted by square and diamond symbols, respectively. A–C show that 6 tumors show little or no staining with either BRG1 or BRM/BRG1 antibodies, whereas the other 54 tumors show >50% staining; the deficient tumors are bolded within TableCitation A. Because the data are incremental, there is overlap of some data points and thus not all symbols are visualized.

 
The other 54 tumors stained positively with both antibodies, indicating they expressed at least BRG1 protein. We previously showed that both antibodies specifically recognize BRG1 and BRG1/BRM, respectively (15) . Of the 6 BRG1-negative tumors, 3 were uniformly devoid of either BRG1 or BRM expression, whereas the other 3 tumors had focal and minimally detectable staining. The loss of BRG1/BRM expression in these tumors was not attributable to staining irregularities because the immunohistochemistry on these samples was repeated to confirm the results, and each sample showed internal positive control staining (normal bronchial epithelial and infiltrating lymphocytes).

Although we have previously observed that the loss of expression of both BRG1 and BRM appear limited to adenocarcinoma cell lines (15) , we also found reduced or absent BRG1 and BRM expression in adenocarcinomas (3 of 41) as well as squamous cell carcinomas (3 of 19; Fig. 2ACitation ). Interestingly, two of these latter carcinomas are adenosquamous type, and loss of BRG1/BRM expression was noted in the area of adenocarcinoma morphology as well as in the area of squamous carcinoma morphology. These results suggest that loss of BRG1 and BRM may not be restricted to adenocarcinomas, as suggested by our original cell line data. Consistent with our previous studies, tumors demonstrated concomitant loss of BRG1 and BRM expression (Fig. 2A)Citation . However, because the second monoclonal antibody (Transduction Laboratories) detects both BRG1 and BRM proteins (Ref. 15 ; Reisman, unpublished data), we cannot determine whether any of the BRG1-positive tumor samples lack only BRM expression.

Loss of BRM/BRG1 Correlates with a Worse Prognosis in NSCLCs.
We compared the survival of the 6 patients who had BRG1/BRM-negative tumors to the 54 patients with BRG1-positive tumors (Fig. 3, B and D)Citation . During a median 36-month follow-up period, the BRG1-positive patients with stage I, II, and III disease had a survival of 79, 66, and 44%, respectively, consistent with previously published data (Fig. 3Citation ; Ref. 18 ). However, the patients with BRG1-negative tumors had 0% survival during this period (Fig. 3D)Citation . The Kaplan-Meier curves show this survival difference between patients with BRG1-positive and BRG1-negative tumors (Fig. 3B)Citation . Lung cancer patients with stage I, II, and IIIA disease have progressively worse survival despite best therapy (curative surgical resection). Although the patients with BRG1-negative tumors had primarily stage I (2 of 6) and stage II (3 of 6) disease, they had a statistically worse survival (P < 0.03) than patients with the clinically more advanced stage IIIA (BRG1 positive) tumors (Fig. 3C)Citation . This difference in survival is not because of difference in treatment or therapies as all 60 patients were treated with surgery alone without any neoadjuvant or adjuvant therapies. As might be expected, patients with BRG1-negative NSCLC also had worse survival than patients with stage-matched BRG1-positive NSCLC.



View larger version (36K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Loss of BRG1 and BRM expression in NSCLC correlates with reduced survival. To determine whether loss of BRG1/BRM expression was clinically significant, the survival of patients with BRG1/BRM-positive tumors (N = 54) was compared with the survival of patients with BRG1/BRM-negative tumors (N = 6). These patients were stage I (n = 37), stage II (n = 13), and stage IIIA (n = 10) at diagnosis and were treated with intent to cure with surgery (A). The median follow-up was 36 months from years 1997 to 2002. The Kaplan-Meier Curve in Fig. 3Citation B shows statistically significant differences (P < 0.0001) in the survival of patients with BRG1/BRM-positive tumors compared with patients with BRG1/BRM-negative tumors. The patients with BRG1/BRM-negative tumors were all deceased within 29 months. Although these two groups were not balanced with respect to stage, which in turn correlates with survival, the patients with BRG1/BRM-negative tumors (primarily stages I and II) have statistically worse survival (P = 0.03) when compared with the patients with BRG1/BRM-positive stage IIIA tumors (Kaplan-Meier Curves Graph 3C). The 1-year, 2-year, 3-year, and median survival of these two groups are shown in D.

 

   Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
REFERENCES
 
SWI/SNF complex subunits were first implicated in tumorigenesis when INI1/hSNF5/BAF47 was recognized as a tumor suppressor. The expression of this protein is lost in pediatric rhabdoid tumors and certain central nervous system tumors secondary to inactivating mutations and gene deletions (1 , 2 , 19) . We show that like INI1/hSNF5/BAF47, the SWI/SNF ATPase subunits, BRG1 and BRM proteins, are also lost in a subset of primary human tumors. This finding, together with transgenic animal data showing that loss of BRG1 is tumorigenic and that BRM is involved in proliferation, supports that BRG1 and BRM are tumor suppressor proteins. Mechanistically, cell line data additionally supports this concept by showing that BRG1 and BRM expression is required for RB-mediated growth inhibition (12 , 15 , 20) . Thus, the loss of BRG1/BRM may serve to abrogate the RB pathway similar to the loss of p16 and/or RB function in human tumors.

The loss of function of the SWI/SNF complex will likely produce major phenotypic changes within tumors because of its interaction and requirement in many signal transduction pathways in addition to the RB pathway. BRG1 and BRM have been shown to interact with cyclin E, Myo-D, p53, p107, and p130 (RB2; Ref. 2 , 11 , 21 , 22 ). Their function is also required for the function of estrogen, glucocorticoid, progesterone, and retinoic acid receptors (19) . Another affect of BRG1/BRM loss may come from the SWI/SNF complex’s contribution, via BAF60a, to the induction of AP1 responsive genes (23) . The number of genes actually regulated by the SWI/SNF complex is at least 80 and in yeast the SWI/SNF complex regulates 5–7% of the yeast genome (24) . Thus, the broad changes in the signaling pathways that must occur with loss of BRG1/BRM must have an impact on the tumor phenotype. Our data suggest that this loss may be an important indicator of a patient’s overall survival.

As with human cancer cell lines, primary tumors appear to have concomitant loss of both BRG1 and BRM protein expression. Because experiments with human tumor cell lines show that BRG1 and BRM have redundant functions (12 , 15 , 25) , their concomitant loss may be required to completely inactivate the SWI/SNF complex. However, biochemical analyses by several groups have shown that BRM and BRG1 are contained in different complexes that, in turn, have apparently different biochemical functions (26 , 27) . Whether the concomitant loss of BRG1 and BRM expression is required to abrogate separate SWI/SNF functions or occurs because BRG1 and BRM share redundant functions important for tumorigenesis, warrants additional investigation.


   ACKNOWLEDGMENTS
 
We thank Dr. Dominic Moore for his assistance with the statistical analysis. We also thank Dr. Moshe Yaniv and Dr. Christian Murchardt for their gift of the BRM specific antisera, and Dr. Pierre Chambon for his gift of the BRG1 monoclonal antibody.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported, in part, by NIH Grant CA91048 (to B. E. W.). D. N. R. received support from NIH Grant T32CA09156 and the Kempner Foundation, University of Texas Medical Branch, Galveston, TX. Back

2 Present address: Division of Hematology/Oncology Department of Medicine, University of Michigan, Ann Arbor, MI 48108. Back

3 To whom requests for reprints should be addressed. Phone: (919) 966-7533; Fax: (919) 966-9673; E-mail: weissman{at}med.unc.edu Back

4 The abbreviations used are: RB, retinoblastoma; NSCLC, non-small cell lung cancer. Back

Received 9/20/02. Accepted 12/13/02.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Klochendler-Yeivin A., Yaniv M. Chromatin modifiers and tumor suppression. Biochim. Biophys. Acta, 1551: M1-M10, 2001.[Medline]
  2. Muchardt C., Yaniv M. When the SWI/SNF complex remodels. the cell cycle. Oncogene, 20: 3067-3075, 2001.[Medline]
  3. Versteege I., Sevenet N., Lange J., Rousseau-Merck M. F., Ambros P., Handgretinger R., Aurias A., Delattre O. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature (Lond.), 394: 203-206, 1998.[Medline]
  4. Klochendler-Yeivin A., Fiette L., Barra J., Muchardt C., Babinet C., Yaniv M. The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression. EMBO Rep., 1: 500-506, 2000.[Medline]
  5. Roberts C. W., Galusha S. A., McMenamin M. E., Fletcher C. D., Orkin S. H. Haploinsufficiency of snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc. Natl. Acad. Sci. USA, 97: 13796-13800, 2000.[Abstract/Free Full Text]
  6. Laurent B. C., Treitel M. A., Carlson M. Functional interdependence of the yeast SNF2, SNF5, and SNF6 proteins in transcriptional activation. Proc. Natl. Acad. Sci. USA, 88: 2687-2691, 1991.[Abstract/Free Full Text]
  7. Bultman S., Gebuhr T., Yee D., La Mantia C., Nicholson J., Gilliam A., Randazzo F., Metzger D., Chambon P., Crabtree G., Magnuson T. A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes. Mol. Cell, 6: 1287-1295, 2000.[Medline]
  8. Reyes J. C., Barra J., Muchardt C., Camus A., Babinet C., Yaniv M. Altered control of cellular proliferation in the absence of mammalian Brahma (SNF2{alpha}). EMBO J., 17: 6979-6991, 1998.[Medline]
  9. Barker N., Hurlstone A., Musisi H., Miles A., Bienz M., Clevers H. The chromatin remodelling factor Brg-1 interacts with ß-catenin to promote target gene activation. EMBO J., 20: 4935-4943, 2001.[Medline]
  10. Bochar D. A., Wang L., Beniya H., Kinev A., Xue Y., Lane W. S., Wang W., Kashanchi F., Shiekhattar R. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell, 102: 257-265, 2000.[Medline]
  11. Lee D., Kim J. W., Seo T., Hwang S. G., Choi E. J., Choe J. SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription. J. Biol. Chem., 277: 22330-22337, 2002.[Abstract/Free Full Text]
  12. Strobeck M. W., Knudsen K. E., Fribourg A. F., DeCristofaro M. F., Weissman B. E., Imbalzano A. N., Knudsen E. S. BRG-1 is required for RB-mediated cell cycle arrest. Proc. Natl. Acad. Sci. USA, 97: 7748-7753, 2000.[Abstract/Free Full Text]
  13. Girard L., Zochbauer-Muller S., Virmani A. K., Gazdar A. F., Minna J. D. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res., 60: 4894-4906, 2000.[Abstract/Free Full Text]
  14. DeCristofaro M. F., Betz B. L., Rorie C. J., Reisman D. N., Wang W., Weissman B. E. Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies. J. Cell. Physiol., 186: 136-145, 2001.[Medline]
  15. Reisman D. N., Strobeck M. W., Betz B. L., Sciariotta J., Funkhouser W., Jr., Murchardt C., Yaniv M., Sherman L. S., Knudsen E. S., Weissman B. E. Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest versus CD44 expression. Oncogene, 21: 1196-1207, 2002.[Medline]
  16. Wong A. K., Shanahan F., Chen Y., Lian L., Ha P., Hendricks K., Ghaffari S., Iliev D., Penn B., Woodland A. M., Smith R., Salada G., Carillo A., Laity K., Gupte J., Swedlund B., Tavtigian S. V., Teng D. H., Lees E. BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res., 60: 6171-6177, 2000.[Abstract/Free Full Text]
  17. Strobeck M. W., Reisman D. N., Gunawardena R. W., Betz B. L., Angus S. P., Knudsen K. E., Kowalik T. F., Weissman B. E., Knudsen E. S. Compensation of BRG-1 function by Brm: insight into the role of the core SWI/SNF subunits in RB-signaling. J. Biol. Chem., 277: 4782-4789, 2002.[Abstract/Free Full Text]
  18. Detterbeck F. C., Rivera P. M., Socinski M. A., Roseman J. C. . Diagnosis and Treatment of Lung Cancer, 177-197, W. B. Company Philadelphia 2001.
  19. Jacobson S., Pillus L. Modifying chromatin and concepts of cancer. Curr. Opin. Genet. Dev., 9: 175-184, 1999.[Medline]
  20. Zhang H. S., Gavin M., Dahiya A., Postigo A. A., Ma D., Luo R. X., Harbour J. W., Dean D. C. Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell, 101: 79-89, 2000.[Medline]
  21. de La Serna I. L., Carlson K. A., Imbalzano A. N. Mammalian SWI/SNF complexes promote MyoD-mediated muscle differentiation. Nat. Genet., 27: 187-190, 2001.[Medline]
  22. Shanahan F., Seghezzi W., Parry D., Mahony D., Lees E. Cyclin E associates with BAF155 and BRG1, components of the mammalian SWI-SNF complex, and alters the ability of BRG1 to induce growth arrest. Mol. Cell. Biol., 19: 1460-1469, 1999.[Abstract/Free Full Text]
  23. Ito T., Yamauchi M., Nishina M., Yamamichi N., Mizutani T., Ui M., Murakami M., Iba H. Identification of SWI/SNF complex subunit BAF60a as a determinant of transactivation potential of Fos/Jun dimers. J. Biol. Chem., 276: 2852-2857, 2000.[Abstract/Free Full Text]
  24. Sudarsanam P., Iyer V. R., Brown P. O., Winston F. Whole-genome expression analysis of snf/swi mutants of Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA, 97: 3364-3369, 2000.[Abstract/Free Full Text]
  25. Strobeck M. W., DeCristofaro M. F., Banine F., Weissman B. E., Sherman L. S., Knudsen E. S. The BRG-1 subunit of the SWI/SNF complex regulates CD44 expression. J. Biol. Chem., 276: 9273-9278, 2001.[Abstract/Free Full Text]
  26. Sif S., Saurin A. J., Imbalzano A. N., Kingston R. E. Purification and characterization of mSin3A-containing Brg1 and hBrm chromatin remodeling complexes. Genes Dev., 15: 603-618, 2001.[Abstract/Free Full Text]
  27. Xue Y., Canman J. C., Lee C. S., Nie Z., Yang D., Moreno G. T., Young M. K., Salmon E. D., Wang W. The human SWI/SNF-B chromatin-remodeling complex is related to yeast rsc and localizes at kinetochores of mitotic chromosomes. Proc. Natl. Acad. Sci. USA, 97: 13015-13020, 2000.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Hum Mol GenetHome page
M. Koga, H. Ishiguro, S. Yazaki, Y. Horiuchi, M. Arai, K. Niizato, S. Iritani, M. Itokawa, T. Inada, N. Iwata, et al.
Involvement of SMARCA2/BRM in the SWI/SNF chromatin-remodeling complex in schizophrenia
Hum. Mol. Genet., July 1, 2009; 18(13): 2483 - 2494.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. Rodriguez-Nieto and M. Sanchez-Cespedes
BRG1 and LKB1: tales of two tumor suppressor genes on chromosome 19p and lung cancer
Carcinogenesis, April 1, 2009; 30(4): 547 - 554.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Shen, N. Powers, N. Saini, C. E.S. Comstock, A. Sharma, K. Weaver, M. P. Revelo, W. Gerald, E. Williams, W. J. Jessen, et al.
The SWI/SNF ATPase Brm Is a Gatekeeper of Proliferative Control in Prostate Cancer
Cancer Res., December 15, 2008; 68(24): 10154 - 10162.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Lin, P. Xu, P. LaVallee, and J. R. Hoidal
Identification of Proteins Binding to E-Box/Ku86 Sites and Function of the Tumor Suppressor SAFB1 in Transcriptional Regulation of the Human Xanthine Oxidoreductase Gene
J. Biol. Chem., October 31, 2008; 283(44): 29681 - 29689.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
E. S. McKenna, C. G. Sansam, Y.-J. Cho, H. Greulich, J. A. Evans, C. S. Thom, L. A. Moreau, J. A. Biegel, S. L. Pomeroy, and C. W. M. Roberts
Loss of the Epigenetic Tumor Suppressor SNF5 Leads to Cancer without Genomic Instability
Mol. Cell. Biol., October 15, 2008; 28(20): 6223 - 6233.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
T. Fujita, J. Igarashi, E. R. Okawa, T. Gotoh, J. Manne, V. Kolla, J. Kim, H. Zhao, B. R. Pawel, W. B. London, et al.
CHD5, a Tumor Suppressor Gene Deleted From 1p36.31 in Neuroblastomas
J Natl Cancer Inst, July 2, 2008; 100(13): 940 - 949.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. A. Link, S. Balasubramaniam, A. Sharma, C. E.S. Comstock, S. Godoy-Tundidor, N. Powers, K. H. Cao, A. Haelens, F. Claessens, M. P. Revelo, et al.
Targeting the BAF57 SWI/SNF Subunit in Prostate Cancer: A Novel Platform to Control Androgen Receptor Activity
Cancer Res., June 15, 2008; 68(12): 4551 - 4558.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Glaros, G. M. Cirrincione, A. Palanca, D. Metzger, and D. Reisman
Targeted Knockout of BRG1 Potentiates Lung Cancer Development
Cancer Res., May 15, 2008; 68(10): 3689 - 3696.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Q. Xi, W. He, X. H.-F. Zhang, H.-V. Le, and J. Massague
Genome-wide Impact of the BRG1 SWI/SNF Chromatin Remodeler on the Transforming Growth Factor Transcriptional Program
J. Biol. Chem., January 11, 2008; 283(2): 1146 - 1155.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Xu, J. Zhang, and X. Chen
The Activity of p53 Is Differentially Regulated by Brm- and Brg1-containing SWI/SNF Chromatin Remodeling Complexes
J. Biol. Chem., December 28, 2007; 282(52): 37429 - 37435.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Yamamichi, K.-i. Inada, M. Ichinose, M. Yamamichi-Nishina, T. Mizutani, H. Watanabe, K. Shiogama, M. Fujishiro, T. Okazaki, N. Yahagi, et al.
Frequent Loss of Brm Expression in Gastric Cancer Correlates with Histologic Features and Differentiation State
Cancer Res., November 15, 2007; 67(22): 10727 - 10735.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. W. Gunawardena, S. R. Fox, H. Siddiqui, and E. S. Knudsen
SWI/SNF Activity Is Required for the Repression of Deoxyribonucleotide Triphosphate Metabolic Enzymes via the Recruitment of mSin3B
J. Biol. Chem., July 13, 2007; 282(28): 20116 - 20123.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
J. Zhang, T. Ohta, A. Maruyama, T. Hosoya, K. Nishikawa, J. M. Maher, S. Shibahara, K. Itoh, and M. Yamamoto
BRG1 Interacts with Nrf2 To Selectively Mediate HO-1 Induction in Response to Oxidative Stress
Mol. Cell. Biol., November 1, 2006; 26(21): 7942 - 7952.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
S. Bilodeau, S. Vallette-Kasic, Y. Gauthier, D. Figarella-Branger, T. Brue, F. Berthelet, A. Lacroix, D. Batista, C. Stratakis, J. Hanson, et al.
Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease.
Genes & Dev., October 15, 2006; 20(20): 2871 - 2886.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Coisy-Quivy, O. Disson, V. Roure, C. Muchardt, J.-M. Blanchard, and J.-C. Dantonel
Role for brm in cell growth control.
Cancer Res., May 15, 2006; 66(10): 5069 - 5076.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. G. Nagl Jr., A. Patsialou, D. S. Haines, P. B. Dallas, G. R. Beck Jr., and E. Moran
The p270 (ARID1A/SMARCF1) Subunit of Mammalian SWI/SNF-Related Complexes Is Essential for Normal Cell Cycle Arrest
Cancer Res., October 15, 2005; 65(20): 9236 - 9244.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
L. Wang, R. A. Baiocchi, S. Pal, G. Mosialos, M. Caligiuri, and S. Sif
The BRG1- and hBRM-Associated Factor BAF57 Induces Apoptosis by Stimulating Expression of the Cylindromatosis Tumor Suppressor Gene
Mol. Cell. Biol., September 15, 2005; 25(18): 7953 - 7965.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. M. Melnick, K. Adelson, and J. D. Licht
The Theoretical Basis of Transcriptional Therapy of Cancer: Can It Be Put Into Practice?
J. Clin. Oncol., June 10, 2005; 23(17): 3957 - 3970.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. N. Bhalla
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
J. Clin. Oncol., June 10, 2005; 23(17): 3971 - 3993.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
R. J. Gibbons
Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes
Hum. Mol. Genet., April 15, 2005; 14(suppl_1): R85 - R92.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
P. P. Medina, J. Carretero, E. Ballestar, B. Angulo, F. Lopez-Rios, M. Esteller, and M. Sanchez-Cespedes
Transcriptional targets of the chromatin-remodelling factor SMARCA4/BRG1 in lung cancer cells
Hum. Mol. Genet., April 1, 2005; 14(7): 973 - 982.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Z. Ma, M. J. Chang, R. Shah, J. Adamski, X. Zhao, and E. N. Benveniste
Brg-1 Is Required for Maximal Transcription of the Human Matrix Metalloproteinase-2 Gene
J. Biol. Chem., October 29, 2004; 279(44): 46326 - 46334.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
A. H. Lund and M. van Lohuizen
Epigenetics and cancer
Genes & Dev., October 1, 2004; 18(19): 2315 - 2335.
[Abstract] [Full Text] [PDF]

Home page
 GeneticsHome page
C. B. Zraly, D. R. Marenda, and A. K. Dingwall
SNR1 (INI1/SNF5) Mediates Important Cell Growth Functions of the Drosophila Brahma (SWI/SNF) Chromatin Remodeling Complex
Genetics, September 1, 2004; 168(1): 199 - 214.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. W. Gunawardena, H. Siddiqui, D. A. Solomon, C. N. Mayhew, J. Held, S. P. Angus, and E. S. Knudsen
Hierarchical Requirement of SWI/SNF in Retinoblastoma Tumor Suppressor-mediated Repression of Plk1
J. Biol. Chem., July 9, 2004; 279(28): 29278 - 29285.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Fukuoka, T. Fujii, J. H. Shih, T. Dracheva, D. Meerzaman, A. Player, K. Hong, S. Settnek, A. Gupta, K. Buetow, et al.
Chromatin Remodeling Factors and BRM/BRG1 Expression as Prognostic Indicators in Non-Small Cell Lung Cancer
Clin. Cancer Res., July 1, 2004; 10(13): 4314 - 4324.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Medjkane, E. Novikov, I. Versteege, and O. Delattre
The Tumor Suppressor hSNF5/INI1 Modulates Cell Growth and Actin Cytoskeleton Organization
Cancer Res., May 15, 2004; 64(10): 3406 - 3413.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. Oruetxebarria, F. Venturini, T. Kekarainen, A. Houweling, L. M. P. Zuijderduijn, A. Mohd-Sarip, R. G. J. Vries, R. C. Hoeben, and C. P. Verrijzer
p16INK4a Is Required for hSNF5 Chromatin Remodeler-induced Cellular Senescence in Malignant Rhabdoid Tumor Cells
J. Biol. Chem., January 30, 2004; 279(5): 3807 - 3816.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
K. B. Hendricks, F. Shanahan, and E. Lees
Role for BRG1 in Cell Cycle Control and Tumor Suppression
Mol. Cell. Biol., January 1, 2004; 24(1): 362 - 376.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
Genomic Response of Saccharomyces cerevisiae to Radical Mediated DNA Damage: JOSEPH P. COSGROVE, THOMAS J. BEGLEY, AND PETER C. DEDON, Division of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139
Toxicol Pathol, January 1, 2004; 32(1): 166 - 166.
[PDF]

Home page
 Mol. Cell. Biol.Home page
S. Pal, R. Yun, A. Datta, L. Lacomis, H. Erdjument-Bromage, J. Kumar, P. Tempst, and S. Sif
mSin3A/Histone Deacetylase 2- and PRMT5-Containing Brg1 Complex Is Involved in Transcriptional Repression of the Myc Target Gene cad
Mol. Cell. Biol., November 1, 2003; 23(21): 7475 - 7487.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reisman, D. N.
Right arrow Articles by Weissman, B. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reisman, D. N.
Right arrow Articles by Weissman, B. E.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online